188 related articles for article (PubMed ID: 25196672)
1. Aberrant methylation of CDH13 is a potential biomarker for predicting the recurrence and progression of non muscle invasive bladder cancer.
Lin YL; Xie PG; Ma JG
Med Sci Monit; 2014 Sep; 20():1572-7. PubMed ID: 25196672
[TBL] [Abstract][Full Text] [Related]
2. Clinical significance of protocadherin 8 (PCDH8) promoter methylation in non-muscle invasive bladder cancer.
Lin YL; Wang YL; Ma JG; Li WP
J Exp Clin Cancer Res; 2014 Aug; 33(1):68. PubMed ID: 25927589
[TBL] [Abstract][Full Text] [Related]
3. Ras association domain family 1A: a promising prognostic marker in recurrent nonmuscle invasive bladder cancer.
Kim JS; Chae Y; Ha YS; Kim IY; Byun SS; Yun SJ; Kim WJ
Clin Genitourin Cancer; 2012 Jun; 10(2):114-20. PubMed ID: 22382007
[TBL] [Abstract][Full Text] [Related]
4. RUNX3 methylation as a predictor for disease progression in patients with non-muscle-invasive bladder cancer.
Yan C; Kim YW; Ha YS; Kim IY; Kim YJ; Yun SJ; Moon SK; Bae SC; Kim WJ
J Surg Oncol; 2012 Mar; 105(4):425-30. PubMed ID: 22311819
[TBL] [Abstract][Full Text] [Related]
5. The prognostic value of P-cadherin in non-muscle-invasive bladder cancer.
Wang P; Lin SL; Zhang LH; Li Z; Liu Q; Gao JX; Liu DM; Bo JJ; Huang YR
Eur J Surg Oncol; 2014 Mar; 40(3):255-9. PubMed ID: 24429027
[TBL] [Abstract][Full Text] [Related]
6. Clinical significance of CDH13 promoter methylation in serum samples from patients with bladder transitional cell carcinoma.
Lin YL; Sun G; Liu XQ; Li WP; Ma JG
J Int Med Res; 2011; 39(1):179-86. PubMed ID: 21672320
[TBL] [Abstract][Full Text] [Related]
7. Ki-67 is an independent indicator in non-muscle invasive bladder cancer (NMIBC); combination of EORTC risk scores and Ki-67 expression could improve the risk stratification of NMIBC.
Ding W; Gou Y; Sun C; Xia G; Wang H; Chen Z; Tan J; Xu K; Qiang D
Urol Oncol; 2014 Jan; 32(1):42.e13-9. PubMed ID: 24360660
[TBL] [Abstract][Full Text] [Related]
8. Snail is an independent prognostic indicator for predicting recurrence and progression in non-muscle-invasive bladder cancer.
Gou Y; Ding W; Xu K; Wang H; Chen Z; Tan J; Xia G; Ding Q
Int Urol Nephrol; 2015 Feb; 47(2):289-93. PubMed ID: 25388353
[TBL] [Abstract][Full Text] [Related]
9. RSPH9 methylation pattern as a prognostic indicator in patients with non-muscle invasive bladder cancer.
Yoon HY; Kim YJ; Kim JS; Kim YW; Kang HW; Kim WT; Yun SJ; Ryu KH; Lee SC; Kim WJ
Oncol Rep; 2016 Feb; 35(2):1195-203. PubMed ID: 26575865
[TBL] [Abstract][Full Text] [Related]
10. Low expression of protocadherin7 (PCDH7) is a potential prognostic biomarker for primary non-muscle invasive bladder cancer.
Lin YL; Wang YL; Fu XL; Li WP; Wang YH; Ma JG
Oncotarget; 2016 May; 7(19):28384-92. PubMed ID: 27070091
[TBL] [Abstract][Full Text] [Related]
11. Cell-cycle markers do not improve discrimination of EORTC and CUETO risk models in predicting recurrence and progression of non-muscle-invasive high-grade bladder cancer.
Passoni N; Gayed B; Kapur P; Sagalowsky AI; Shariat SF; Lotan Y
Urol Oncol; 2016 Nov; 34(11):485.e7-485.e14. PubMed ID: 27637323
[TBL] [Abstract][Full Text] [Related]
12. Promoter methylation of H-cadherin is a potential biomarker in patients with bladder transitional cell carcinoma.
Lin YL; Liu XQ; Li WP; Sun G; Zhang CT
Int Urol Nephrol; 2012 Feb; 44(1):111-7. PubMed ID: 21516472
[TBL] [Abstract][Full Text] [Related]
13. HMOX1 is an important prognostic indicator of nonmuscle invasive bladder cancer recurrence and progression.
Yim MS; Ha YS; Kim IY; Yun SJ; Choi YH; Kim WJ
J Urol; 2011 Feb; 185(2):701-5. PubMed ID: 21168882
[TBL] [Abstract][Full Text] [Related]
14. Prognostic DNA Methylation Biomarkers in High-risk Non-muscle-invasive Bladder Cancer: A Systematic Review to Identify Loci for Prospective Validation.
Gurung PMS; Barnett AR; Wilson JS; Hudson J; Ward DG; Messing EM; Bryan RT
Eur Urol Focus; 2020 Jul; 6(4):683-697. PubMed ID: 30803927
[TBL] [Abstract][Full Text] [Related]
15. Quantitative genome-wide methylation analysis of high-grade non-muscle invasive bladder cancer.
Kitchen MO; Bryan RT; Emes RD; Glossop JR; Luscombe C; Cheng KK; Zeegers MP; James ND; Devall AJ; Mein CA; Gommersall L; Fryer AA; Farrell WE
Epigenetics; 2016 Mar; 11(3):237-46. PubMed ID: 26929985
[TBL] [Abstract][Full Text] [Related]
16. Clinical significance of CDH13 promoter methylation as a biomarker for bladder cancer: a meta-analysis.
Chen F; Huang T; Ren Y; Wei J; Lou Z; Wang X; Fan X; Chen Y; Weng G; Yao X
BMC Urol; 2016 Aug; 16(1):52. PubMed ID: 27578166
[TBL] [Abstract][Full Text] [Related]
17. Can re-cTURBT be useful in pT1HG disease as a risk indicator of recurrence and progression? A single centre experience.
Giulianelli R; Gentile BC; Mirabile G; Albanesi L; Tariciotti P; Rizzo G; Buscarini M; Vermiglio M
Arch Ital Urol Androl; 2017 Dec; 89(4):272-276. PubMed ID: 29473376
[TBL] [Abstract][Full Text] [Related]
18. Liquid Biopsy Analysis of FGFR3 and PIK3CA Hotspot Mutations for Disease Surveillance in Bladder Cancer.
Christensen E; Birkenkamp-Demtröder K; Nordentoft I; Høyer S; van der Keur K; van Kessel K; Zwarthoff E; Agerbæk M; Ørntoft TF; Jensen JB; Dyrskjøt L
Eur Urol; 2017 Jun; 71(6):961-969. PubMed ID: 28069289
[TBL] [Abstract][Full Text] [Related]
19. Hypermethylation of E-cadherin, p16, p14, and RASSF1A genes in pathologically normal urothelium predict bladder recurrence of bladder cancer after transurethral resection.
Lin HH; Ke HL; Wu WJ; Lee YH; Chang LL
Urol Oncol; 2012; 30(2):177-81. PubMed ID: 20800513
[TBL] [Abstract][Full Text] [Related]
20. Promoter methylation of protocadherin8 is an independent prognostic factor for biochemical recurrence of early-stage prostate cancer.
Niu WB; Gui SL; Lin YL; Fu XL; Ma JG; Li WP
Med Sci Monit; 2014 Dec; 20():2584-9. PubMed ID: 25486497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
